GSK, Vir Biotechnology to expand Covid-19 treatment study

This article was originally published here

The companies announced the global expansion to phase 3 of the Covid-19 monoclonal antibody efficacy trial – intent to care early (COMET-ICE) to assess VIR-7831 for the early

The post GSK, Vir Biotechnology to expand Covid-19 treatment study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply